Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
Top Cited Papers
- 1 December 2016
- journal article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 17 (12), 1743-1754
- https://doi.org/10.1016/s1470-2045(16)30578-2
Abstract
No abstract availableKeywords
Funding Information
- Novartis
This publication has 26 references indexed in Scilit:
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in MelanomaNew England Journal of Medicine, 2014
- The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibitionCancer, 2014
- Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic TherapyPLOS ONE, 2013
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced MelanomaJournal of Immunotherapy, 2012
- NRAS mutation status is an independent prognostic factor in metastatic melanomaCancer, 2011
- Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic MelanomaJournal of Clinical Oncology, 2011
- Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanomaCancer, 2010
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- Mutations of the BRAF gene in human cancerNature, 2002